TY - T1的肾与meropen Fanconi综合症em/amoxicillin-clavulanate during treatment of extensively drug-resistant tuberculosis JF - European Respiratory Journal JO - Eur Respir J DO - 10.1183/13993003.02023-2017 VL - 50 IS - 6 SP - 1702023 AU - Abadie, Miriam E. AU - Strich, Jeffrey R. AU - Kim, Tiffany AU - Xie, Yingda L. AU - Fennelly, Kevin P. AU - Olivier, Kenneth N. AU - Waldman, Meryl AU - Arora, Kriti AU - Holland, Steven M. AU - Chen, Ray Y. Y1 - 2017/12/01 UR - //www.qdcxjkg.com/content/50/6/1702023.abstract N2 - We read with interest the papers by Tiberi et al. [1, 2] describing the effectiveness of meropenem/clavulanate in treating multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis (TB) patients. In these analyses, 96 patients were treated with meropenem/clavulanate for a median of 85 (interquartile range (IQR) 49–156) days with six adverse events, and 84 patients were treated with imipenem/clavulanate for a median (IQR) of 187 (60–428) days and three adverse events, none renally related. We report a patient with XDR-TB who developed renal Fanconi syndrome apparently due to meropenem/amoxicillin-clavulanate.Prolonged use of meropenem/amoxicillin-clavulate to treat XDR-TB may be associated with renal Fanconi syndrome http://ow.ly/dFSD30gCKti ER -